PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers

PolarityTE provided a business update and reported financial results for the quarterly period ended September 30, 2022.

PolarityTE confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.

Excess Equipment Sale for BioUtah Members

PolarityTE provided a business update and reported financial results for the quarterly period ended June 30, 2022.

PolarityTE announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor

PolarityTE announced that the Company will effectuate a 1-for-25 reverse stock split of the Company’s issued and outstanding common stock.

PolarityTE provided a business update and reported financial results for the three-month period ended March 31, 2022.

PolarityTE announced that the U.S. FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company’s open IND. 

SALT LAKE CITY, May 3, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational use of treatment of Wagner grade 2 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE,” or “COVER […]

SALT LAKE CITY, March 30, 2022 /PRNewswire/ — PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the twelve-month period ended December 31, 2021. Recent Business and Financial Updates In the first quarter of 2022, PolarityTE received approval from the U.S. […]

PolarityTE Announces $5.0 Million Registered Direct Offering